statements

The stock has been placed in Graded Surveillance Measure (GSM) list GSM - 0.

Transgene Biotek Ltd.

BSE: 526139

Sector: Healthcare

Industry Group: Healthcare Services

Industry: Healthcare Service Provider

3.00+0.0 (+0.67%)

27 Jul, 12:00 AM

Overview Analysis Statements

Technicals Forecast Peers Resources News

Income Statement

Abridged

Understanding Income Statement

Transgene Biotek Ltd. income statement covering revenue, operating profit, EBITDA, PAT and EPS across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	26.33	15.03	0.98	0.33	0.18	0.28	0.12	0.07	0.00	0.17	0.09	0.06	0.23	0.26	0.21
Cost of Operating Revenue	22.96	16.28	17.46	17.19	20.50	17.53	9.94	9.93	9.91	9.97	9.88	5.02	0.09	0.09	0.20
Gross Profit	3.37	-1.25	-16.47	-16.86	-20.32	-17.25	-9.82	-9.86	-9.91	-9.80	-9.79	-4.96	0.14	0.17	0.01
Gross Margin	12.8	-8.3	-1,679.1	-5,067.2	-11,194.0	-6,140.8	-8,306.8	-13,826.4	-2,76,763.4	-5,779.6	-11,294.8	-9,007.5	60.5	64.3	5.7
Total Operating Expenses	25.88	17.94	19.97	19.11	21.82	20.37	12.12	10.65	10.76	10.60	10.47	6.06	0.94	1.48	0.95
Operating Profit	0.44	-2.91	-18.99	-18.78	-21.63	-20.09	-12.00	-10.58	-10.76	-10.44	-10.39	-6.00	-0.71	-1.22	-0.74
Operating Margin	1.7	-19.4	-1,935.6	-5,642.3	-11,916.7	-7,152.6	-10,146.3	-14,840.7	-3,00,574.9	-6,154.7	-11,982.7	-10,898.0	-301.8	-466.7	-351.6
Financing Income/(Expense) - Net	-0.62	-0.20	0.00	-0.36	-0.07	-0.43	-1.03	-0.25	-0.38	-0.27	-0.23	-0.18	-0.13	-0.24	-1.06
Profit before Taxes	17.19	-2.03	-133.41	-19.14	-21.54	-19.86	-5.65	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66	-0.68	-1.65
Income Taxes	5.60	-	-	-	-	-	0.79	-	-	-	-	-	-	-	-
Profit after Tax	11.60	-2.03	-133.41	-19.14	-21.54	-19.86	-6.44	-8.79	-10.96	-10.43	-10.40	-6.01	-0.66	-0.68	-1.65
PAT Margin	44.0	-13.5	-13,597.7	-5,750.4	-11,864.3	-7,071.6	-5,445.3	-12,333.7	-3,06,207.8	-6,154.3	-11,999.1	-10,908.9	-279.1	-259.3	-782.6
EPS - Basic - ex Extraordinary Items	1.76	-0.31	-17.61	-2.53	-2.84	-2.62	-0.85	-1.16	-1.45	-1.38	-1.37	-0.79	-0.09	-0.09	-0.22
EPS - Diluted - ex Extraordinary Items	1.76	-0.31	-17.61	-2.53	-2.84	-2.62	-0.85	-1.16	-1.45	-1.38	-1.37	-0.79	-0.09	-0.09	-0.22
EBIT	0.44	-2.91	-18.99	-18.78	-21.63	-20.09	-12.00	-10.58	-10.76	-10.44	-10.39	-6.00	-0.71	-1.22	-0.74
EBITDA	1.20	-0.88	-1.78	-1.60	-1.13	-2.56	-2.11	-0.69	-0.86	-0.53	-0.46	-1.05	-0.62	-1.12	-0.54
EBITDA Margin	4.5	-5.8	-180.9	-479.4	-623.1	-911.9	-1,780.7	-961.8	-24,124.9	-311.0	-534.5	-1,910.9	-262.5	-430.9	-257.3

Balance Sheet

Abridged

Understanding Balance Sheet

Transgene Biotek Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	C 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	C 2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	31.16	20.74	20.22	18.26	3.46	0.78	0.79	0.65	0.68	0.65	0.70	1.04	1.11	1.26	1.03
Long-Term Investments	-	-	-	-	-	-	-	-	-	-	0.10	0.10	0.10	0.10	0.09
Property Plant & Equipment - Net	7.38	6.74	6.07	5.43	3.75	3.43	2.64	2.40	2.21	2.03	1.85	1.76	1.67	3.29	3.09
Total Non-Current Assets	334.55	347.88	338.12	325.51	309.53	197.29	185.76	175.90	166.07	156.23	146.40	141.31	141.22	142.83	142.63
Total Assets	365.71	368.62	358.34	343.77	312.99	198.07	186.55	176.55	166.75	156.88	147.10	142.36	142.33	144.09	143.66
Total Current Liabilities	48.28	35.06	25.56	25.24	11.33	11.73	13.83	12.54	13.70	14.18	9.21	10.47	11.14	12.74	13.26
Long Term Debt	6.39	5.93	5.93	6.27	6.34	5.19	3.84	4.10	4.28	4.54	4.77	4.95	5.08	6.10	6.80
Total Non-Current Liabilities	6.54	11.63	126.81	127.15	127.22	127.47	120.29	120.37	120.37	120.47	120.52	120.52	120.48	121.32	122.02
Total Liabilities	54.82	46.68	152.37	152.38	138.54	139.20	134.12	132.91	134.08	134.64	129.72	130.99	131.62	134.06	135.28
Total Shareholders' Equity	310.89	321.94	205.97	191.39	174.44	58.87	52.43	43.64	32.67	22.24	17.38	11.37	10.71	10.03	8.38
Total Equity	310.89	321.94	205.97	191.39	174.44	58.87	52.43	43.64	32.67	22.24	17.38	11.37	10.71	10.03	8.38
Total Liabilities & Equity	365.71	368.62	358.34	343.77	312.99	198.07	186.55	176.55	166.75	156.88	147.10	142.36	142.33	144.09	143.66

Cash Flow

Abridged

Understanding Cash Flow Statement

Transgene Biotek Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	18.27	12.06	-117.64	2.95	5.58	-0.62	-2.13	-0.59	-0.86	-0.44	-0.43	-1.05	-0.61	-0.77	-1.60
Working Capital - Increase/(Decrease)	7.08	0.74	115.54	0.57	0.89	0.65	4.32	-0.18	-0.01	-0.29	0.07	0.20	-0.15	2.22	-1.39
Net CF from Operating Activities	25.34	12.80	-2.11	3.52	6.47	0.02	2.19	-0.77	-0.87	-0.72	-0.36	-0.85	-0.75	1.46	-2.99
Capital Expenditures - Net	1.36	93.07	-	-	-	-	-3.37	-1.74	-	0.03	0.00	0.01	-	-	-0.15
Net CF from Investing Activities	-144.22	-15.35	1.45	-4.57	-6.47	-	3.05	1.74	-	-0.03	-0.10	-0.01	-	-1.70	0.15
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-3.71	2.62	-9.40	1.03	-	-	-5.19	-0.97	0.81	0.74	0.46	0.85	0.76	0.52	2.62
Net Cash Flow from Financing Activities	82.79	2.62	0.60	1.03	-	-	-5.19	-0.97	0.81	0.74	0.46	0.85	0.76	0.52	2.62
Free Cash Flow to Equity	20.28	-77.66	-11.51	4.55	-	-	0.37	0.00	-0.06	-0.01	0.10	-0.01	0.00	1.98	-0.22
Free Operating CF net dividend	23.99	-80.28	-2.11	3.52	6.47	0.02	2.19	-0.85	-	-0.75	-0.36	-0.86	-0.75	1.46	-2.99
Free Operating CF	23.99	-80.28	-2.11	3.52	6.47	0.02	2.19	-0.85	-	-0.75	-0.36	-0.86	-0.75	1.46	-2.99

Business Segment Analysis

FY End:

Mar 11

Transgene Biotek Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Revenue / Sales

Agri Biotek Division (40.6%)₹ 6.49 CrBulk Drug (40.6%)₹ 6.49 CrDiagnostics Products (18.7%)₹ 2.99 Cr

Operating Income

Bulk Drug (37.4%)₹ 1.35 CrAgri Biotek Division (36.3%)₹ 1.31 CrDiagnostics Products (26.4%)₹ 0.95 CrE API DHA (0.0%)₹ 0.00 CrTechnology Outsourcing (0.0%)₹ 0.00 Cr

Regional Segment Analysis

Transgene Biotek Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

We don't have enough data to show regional segment analysis for Transgene Biotek Ltd.

Historical Segment Analysis

Track how Transgene Biotek Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Sales

Operating Income

Business

Regional

Business

We don't have enough data to show the Capex for Transgene Biotek Ltd..

Frequently Asked Questions

What is the revenue of Transgene Biotek Ltd.?

The latest trailing twelve month revenue of Transgene Biotek Ltd. is ₹ 0.21 Cr, reflecting a 1-year growth of -18.99% and a 3-year CAGR of 56.52%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Transgene Biotek Ltd.?

The latest trailing twelve month net profit (PAT) of Transgene Biotek Ltd. is ₹ -1.65 Cr, with a 3-year earnings CAGR of 34.78%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Transgene Biotek Ltd.?

The trailing twelve month EBITDA of Transgene Biotek Ltd. is approximately ₹ -0.74 Cr (based on an operating margin of -351.61%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Transgene Biotek Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Transgene Biotek Ltd. is -0.22. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Transgene Biotek Ltd.?

The debt-to-equity ratio of Transgene Biotek Ltd. stands at 2.05. The interest coverage ratio is -0.70x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Transgene Biotek Ltd.?

The estimated book value per share of Transgene Biotek Ltd. is 1.11 (derived from a P/B ratio of 2.71 and market price of ₹ 3.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Transgene Biotek Ltd.?

The trailing twelve month operating cash flow of Transgene Biotek Ltd. is ₹ -2.99 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Transgene Biotek Ltd. report consolidated or standalone financials?

Transgene Biotek Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.